

# Analysis of key genes and pathways in breast ductal carcinoma *in situ*

MIN WU<sup>1</sup> and HONGMEI ZHAO<sup>2</sup>

<sup>1</sup>Department of General Surgery, Beijing Youan Hospital, Capital Medical University, Beijing 100069;

<sup>2</sup>Department of General Surgery, Peking University Third Hospital, Beijing 100191, P.R. China

Received March 15, 2019; Accepted September 17, 2019

DOI: 10.3892/ol.2020.12080

**Abstract.** Breast cancer (BC) remains the most common cancer in females. Therefore, the present study aimed to identify key genes involved in the carcinogenesis of BC and to explore their prognostic values by integrating bioinformatics tools. The gene expression profiles of 46 ductal carcinoma *in situ* (DCIS) and three normal breast tissues from the GSE59248 dataset were downloaded. Differentially expressed genes (DEGs) were subsequently identified using the online tool GEO2R and a functional enrichment analysis was performed. In addition, a protein-protein interaction (PPI) network was constructed and the top eight hub genes were identified. The prognostic values of the hub genes were further investigated. A total of 316 DEGs, including 32 upregulated and 284 downregulated genes, were identified. Furthermore, eight hub genes, including lipase E hormone sensitive type, patatin like phospholipase domain containing 2, adiponectin C1Q and collagen domain containing (ADIPOQ), peroxisome proliferator activated receptor  $\gamma$  (PPARG), fatty acid binding protein 4 (FABP4), diacylglycerol O-acyltransferase 2, lipoprotein lipase (LPL) and leptin (LEP), were identified from the PPI network. The downregulated expression of ADIPOQ, PPARG, FABP4, LPL and LEP was significantly associated with poor overall survival in patients with DCIS. Therefore, these genes may serve as potential biomarkers for prognosis prediction. However, further investigation is required to validate the results obtained in the present study.

## Introduction

Breast cancer (BC) is the most common cancer and the major cause of cancer-associated mortalities among women worldwide (1). A total of 2,088,849 new cases and

626,679 mortalities were reported globally for BC in 2018 (2). It was also reported that the 5-year survival rate of patients with BC during 2007-2013 was 90% in the USA. The standard treatment modalities for BC include surgery, radiation, chemotherapy, targeted therapy and hormone therapy (3-5). Ductal carcinoma *in situ* (DCIS) is the earliest stage of BC and refers to a heterogeneous group of precursor lesions (6). Approximately 20-25% of patients with BC are diagnosed with DCIS (7). While not all DCIS cases progress to invasive BC, DCIS is usually excised as its potential for invasion remains difficult to predict (8).

Previous studies have focused on analyzing the molecular differences between DCIS and invasive BC and the potential progression mechanisms (9-12). The upregulation of erb-b2 receptor tyrosine kinase 2 (ERBB2) is considered to be an early step in the progression of DCIS (13,14). Shah *et al* (13) revealed that the downregulation of Rap1Gap, a GTPase-activating protein, promotes the progression of DCIS to invasive ductal carcinoma by activating the extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway. In the phosphoinositide 3-kinase signaling pathway alterations have also been reported to be associated with the progression of DCIS (14). Additionally, the upregulation of cyclin D1, MYC proto-oncogene bHLH transcription factor and ERBB2, have previously been observed in DCIS (15). The upregulation of matrix metalloproteinase (MMPs), including MMP2, and downregulation of cadherin 1 are frequently observed in the progression from DCIS to invasive BC via the epithelial-mesenchymal transition (9,16). Previous studies have revealed that certain biomarkers, including the ki67 proliferation marker, the tumor protein p53 tumor suppressor gene and the estrogen receptor, may serve as prognostic predictors in DCIS (17,18). However, further investigation of the molecular features and differences between DCIS and normal breast tissues is required. Therefore, the aim of the present study was to identify key genes involved in DCIS and to explore their prognostic values by integrating bioinformatics tools.

## Materials and methods

**Gene expression level analysis of DCIS and normal breast tissue samples.** The gene expression profiles of 46 DCIS and three normal breast tissues in the GSE59248 dataset (19) were downloaded from the Gene Expression Omnibus

---

**Correspondence to:** Dr Hongmei Zhao, Department of General Surgery, Peking University Third Hospital, 49 North Garden Road, Haidian, Beijing 100191, P.R. China  
E-mail: hongmeizhaobysy@163.com

**Key words:** bioinformatics, ductal carcinoma *in situ*, hub genes, protein-protein interactions

(GEO) (<https://www.ncbi.nlm.nih.gov/geo/>). This dataset was analyzed using the Agilent-028004 SurePrint G3 Human GE 8x60K Microarray platform (Agilent Technologies, Inc.). The online tool GEO2R ([www.ncbi.nlm.nih.gov/geo/geo2r](http://www.ncbi.nlm.nih.gov/geo/geo2r)) was subsequently used to identify the differentially expressed genes (DEGs) between DCIS and normal breast tissues using the Benjamini and Hochberg false discovery rate (20). The cut-off criteria for the selection of DEGs were an adjusted  $P < 0.05$  and a  $\log_2$  fold-change  $> 2$ .

**Functional enrichment analyses of the DEGs.** Gene Ontology (GO) (<http://geneontology.org>) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to explore the biological functions of the DEGs. GO functional analysis, which includes biological processes, cellular components and molecular functions, was performed using the Protein Analysis Through Evolutionary Relationships (PANTHER) classification system (16). KEGG pathways enrichment analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID; version 6.8) (<https://david.ncifcrf.gov>) (17). The criteria for significance were  $P < 0.05$  and the number of enriched DEGs in pathways  $\geq 5$ .

**Construction of the protein-protein interaction (PPI) network.** To further explore the associations between the identified DEGs, a PPI network was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (<https://string-db.org>) (18) and visualized using Cytoscape software (version 3.6.1) (21). In the PPI network, the nodes and edges represent proteins and their interactions, respectively. The genes in the PPI network with the highest connectivity were considered hub genes. The potential hub genes were screened from the entire PPI network using the cytoHubba plug-in and the maximal clique centrality algorithm (22,23).

**Survival analysis of hub genes with the log-rank test.** To evaluate the prognostic values of the identified hub genes in patients with DCIS, an overall survival (OS) analysis was carried out using the Kaplan-Meier plotter (<https://kmplot.com/analysis/>), which is a web-based tool to assess the effect of 54,675 genes on survival in 21 cancer types (24).

**Statistical analysis.** SPSS software (version 22.0; IBM Corp.) was used to perform the statistical analysis. The data were presented with mean  $\pm$  SD. The associations between the clinicopathological parameters and hub gene expression were analyzed using the  $\chi^2$  test. When the sample size was  $< 40$ , the Fisher's exact test was applied.  $P < 0.05$  was considered to indicate a statistically significant difference. The  $\alpha$  level was 0.05.

## Results

**DEGs between DCIS and normal tissue samples.** A total of 316 DEGs, including 32 upregulated and 284 downregulated genes, were identified in the GSE59248 dataset. The GSE59248 dataset included the gene expression profiles of 46 DCIS and 3 normal breast tissue samples.

Table I. Functional enrichment analyses of the differentially expressed genes in ductal carcinoma *in situ* using the Protein Analysis Through Evolutionary Relationships classification system. The top eight items with its counting percentage in each category were present.

| A, Protein categories                         |            |
|-----------------------------------------------|------------|
| Term                                          | Percentage |
| Hydrolase                                     | 12.60      |
| Signaling molecule                            | 10.20      |
| Enzyme modulator                              | 8.70       |
| Transcription factor                          | 7.80       |
| Transporter                                   | 7.80       |
| Nucleic acid binding                          | 7.30       |
| Transferase                                   | 6.80       |
| Receptor                                      | 6.80       |
| B, Cellular component                         |            |
| Term                                          | Percentage |
| Cell part                                     | 35.50      |
| Organelle                                     | 20.30      |
| Membrane                                      | 19.50      |
| Macromolecular complex                        | 12.60      |
| Extracellular region                          | 8.70       |
| Cell junction                                 | 2.20       |
| Synapse                                       | 0.90       |
| Extracellular matrix                          | 0.40       |
| C, Biological process                         |            |
| Term                                          | Percentage |
| Cellular process                              | 25.80      |
| Metabolic process                             | 16.70      |
| Biological regulation                         | 11.00      |
| Developmental process                         | 10.60      |
| Response to stimulus                          | 9.50       |
| Multicellular organismal process              | 8.40       |
| Localization                                  | 6.10       |
| Cellular component organization or biogenesis | 3.90       |
| D, Molecular function                         |            |
| Term                                          | Percentage |
| Binding                                       | 38.90      |
| Catalytic activity                            | 35.10      |
| Transporter activity                          | 8.50       |
| Receptor activity                             | 7.60       |
| Signal transducer activity                    | 5.70       |
| Structural molecule activity                  | 3.30       |
| Channel regulator activity                    | 0.90       |




Figure 1. Gene Ontology and functional enrichment analyses of the differentially expressed genes in ductal carcinoma *in situ*. (A) Protein categories, (B) cellular component, (C) biological process and (D) molecular function.

**Functional enrichment analyses of the DEGs.** The analytical results of the PANTHER classification system revealed that the identified DEGs could be classified into 22 protein categories, including signaling molecules, transporters, hydrolases, enzyme modulators and transcription factors (Fig. 1A; Table I). The GO analysis revealed that these DEGs were significantly involved in cellular components such as 'cell part', 'organelle', 'membranes' and 'macromolecular complex' (Fig. 1B; Table I). In terms of biological processes, the DEGs are mainly associated with 'metabolic process', 'cellular process', 'biological regulation', 'developmental process' and 'response to stimulus' (Fig. 1C; Table I). Regarding molecular functions, the DEGs were mainly associated with 'catalytic activity', binding, transporter activity and signal transducer activity (Fig. 1D; Table I). The analysis of KEGG pathways using DAVID indicated that the DEGs are mainly enriched in pathways such as 'PPAR signaling pathway', 'AMPK signaling pathway', 'regulation of lipolysis in adipocytes' and 'glucagon signaling pathway' (Fig. 2).

**PPI network and hub genes.** In the present study, the STRING database was used to construct a PPI network to visualize the protein-protein interactions between the DEGs (Fig. 3). The network consisted of a total of 315 nodes and 474 edges. The local clustering coefficient of the PPI network was 0.374 and the average node degree was 3.01. The top eight






Figure 2. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of the differentially expressed genes in ductal carcinoma *in situ*.

hub genes were identified from the PPI network using the cytoHubba plugin and the maximal clique centrality algorithm. The hub genes were as follows: Lipase E hormone sensitive type (LIPE), patatin-like phospholipase domain-containing 2 (PNPLA2), adiponectin (ADIPOQ), peroxisome proliferator activated receptor  $\gamma$  (PPARG), fatty acid-binding protein 4 (FABP4), diacylglycerol O-acyltransferase 2 (DGAT2),



**Survival analysis results of the hub genes.** The prognostic values of the identified hub genes in patients with DCIS were investigated using the Kaplan-Meier plotter. Only the low expression of ADIPOQ [hazard ratio (HR)=0.75; 95% confidence interval (CI), 0.61-0.94; log-rank P=0.01], PPARG (HR=0.66; 95% CI, 0.53-0.82; log-rank P=0.0013), FABP4 (HR=0.76; 95% CI, 0.61-0.94; log-rank P=0.012), LPL (HR=0.75; 95% CI, 0.61-0.93; log-rank P=0.009) and LEP (HR=0.8; 95% CI, 0.64-0.99; log-rank P=0.037) were significantly associated with poor OS in patients with DCIS (Fig. 5). The associations between the hub gene expression levels and clinicopathological parameters of patients with DCIS are presented in Table II. The expression levels of LIPE, PNPLA2 and DGAT2 did not significantly influence the prognosis of patients with DCIS (Fig. S1).

Figure 4. Top eight hub genes screened from the entire protein-protein interaction network. LIPE, lipase E hormone sensitive type; PNPLA2, patatin-like phospholipase domain-containing 2; ADIPOQ, adiponectin; PPARG, peroxisome proliferator activated receptor  $\gamma$ ; FABP4, fatty acid-binding protein 4; DGAT2, diacylglycerol O-acyltransferase 2; LPL, lipoprotein lipase; LEP, leptin.




Figure 5. Overall survival analysis of (A) ADIPOQ, (B) PPARG, (C) FABP4, (D) LPL and (E) LEP in ductal carcinoma *in situ* was performed using the Kaplan-Meier plotter. Red and black represent high and low expression, respectively. ADIPOQ, adiponectin; PPARG, peroxisome proliferator activated receptor  $\gamma$ ; FABP4, fatty acid-binding protein 4; LPL, lipoprotein lipase; LEP, leptin; HR, hazard ratio.

## Discussion

DCIS is a heterogeneous disease and represents the pre-invasive stage of BC (25). Although the majority of patients with DCIS undergo breast excision to remove the lesion, certain patients

with DCIS may still develop invasive BC (26). Therefore, it is important to explore the molecular features of DCIS development and to identify potential prognostic biomarkers.

The present study analyzed the gene expression data of 46 DCIS and three normal breast tissues. A total of 316 DEGs

Table II. The correlation analysis of the hub genes' expression levels and the clinicopathological parameters of Ductal Carcinoma in situ of the Breast (data from the GSE59248 dataset).

| Clinical parameter | No. of cases (n) | ADIPOQ expression |     |         | LEP expression |     |         | LPL expression |     |         | FABP4 expression |     |         | PPARG expression |     |         |
|--------------------|------------------|-------------------|-----|---------|----------------|-----|---------|----------------|-----|---------|------------------|-----|---------|------------------|-----|---------|
|                    |                  | High              | Low | P-value | High           | Low | P-value | High           | Low | P-value | High             | Low | P-value | High             | Low | P-value |
| Age                |                  |                   |     |         |                |     |         |                |     |         |                  |     |         |                  |     |         |
| ≤55                | 19               | 12                | 7   | 0.314   | 14             | 5   | 0.049   | 12             | 7   | 1.00    | 9                | 10  | 0.220   | 12               | 7   | 0.314   |
| >55                | 27               | 13                | 14  |         | 12             | 15  |         | 18             | 9   |         | 8                | 19  |         | 13               | 14  |         |
| Tumor size (cm)    |                  |                   |     |         |                |     |         |                |     |         |                  |     |         |                  |     |         |
| ≤3                 | 22               | 14                | 8   | 0.678   | 14             | 8   | 0.242   | 15             | 7   | 0.417   | 12               | 10  | 0.419   | 12               | 10  | 0.419   |
| >3                 | 8                | 4                 | 4   |         | 3              | 5   |         | 4              | 4   |         | 6                | 2   |         | 6                | 2   |         |
| ER                 |                  |                   |     |         |                |     |         |                |     |         |                  |     |         |                  |     |         |
| Positive           | 15               | 6                 | 9   | 0.105   | 6              | 9   | 0.400   | 7              | 8   | 0.210   | 8                | 7   | 1.00    | 9                | 6   | 1.00    |
| Negative           | 9                | 7                 | 2   |         | 6              | 3   |         | 7              | 2   |         | 5                | 4   |         | 5                | 4   |         |
| PR                 |                  |                   |     |         |                |     |         |                |     |         |                  |     |         |                  |     |         |
| Positive           | 12               | 4                 | 8   | 0.100   | 4              | 8   | 0.220   | 3              | 9   | 0.003   | 5                | 7   | 0.414   | 8                | 4   | 0.680   |
| Negative           | 12               | 9                 | 3   |         | 8              | 4   |         | 11             | 1   |         | 8                | 4   |         | 6                | 6   |         |
| HER2               |                  |                   |     |         |                |     |         |                |     |         |                  |     |         |                  |     |         |
| Positive           | 9                | 6                 | 3   | 0.387   | 5              | 4   | 1.00    | 7              | 2   | 0.080   | 6                | 3   | 0.660   | 6                | 3   | 0.660   |
| Negative           | 12               | 5                 | 7   |         | 6              | 6   |         | 4              | 8   |         | 6                | 6   |         | 6                | 6   |         |

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

were identified, including 32 upregulated and 284 down-regulated genes. The identified DEGs could be classified into 22 protein categories. Moreover, the results of the functional enrichment analysis indicated that the DEGs were mostly associated with cell parts, organelles, metabolic processes, cellular processes, biological regulation, transporter activity and signal transducer activity. A PPI network was constructed and eight hub genes were selected for further investigation. The downregulation of ADIPOQ, PPARG, FABP4, LPL and LEP was significantly associated with poor OS in patients with DCIS.

ADIPOQ encodes an adipocytokine, adiponectin, which is essential for metabolic and hormonal processes (27). A low level of plasma adiponectin has been significantly associated with several types of cancer, including colorectal and prostate cancer (28,29). It was also reported that adiponectin may decrease cancer cell growth by promoting the activity of autophagosomes and decreasing the sequestosome 1/GAP-associated tyrosine phosphoprotein p62 signaling pathway in BC (27). High ADIPOQ expression may serve a protective role in BC (30), consistent with the results obtained in the present study.

PPARG serves an important role in regulating adipocyte differentiation by forming heterodimers with retinoid X receptors (31). Several studies have shown that PPARG serves an anti-inflammatory role and may reduce the risk of breast cancer (32-34). The expression level of PPARG was found to influence the susceptibility to hepatocellular carcinoma (35) and different types of cancer (36). However, the association between PPARG and the risk of BC has not been established (37,38). FABP4 is involved in lipoprotein metabolism (39). A previous study revealed that FABP4 increased cell apoptosis and decreased proliferation (40). FABP4 overexpression has been reported to decrease hepatocellular carcinoma cell growth through the snail family transcriptional repressor 1/p-STAT3 signaling pathway *in vitro* and was associated with tumor size and overall survival in hepatocellular carcinoma (41).

LPL plays a critical role in lipid metabolism (42). Studies have shown that LPL may regulate metabolic pathways to provide additional energy for cancer cells (43,44). Circulating LEP is usually secreted by white adipose tissue and is involved in the regulation of angiogenesis, energy balance, and immune and inflammatory responses (45). Previous studies revealed that LEP altered the cellular response to estrogens in BC and served a role in mammary carcinogenesis (46,47). Furthermore, LEP may promote cell cycle progression by upregulating the levels of cyclin dependent kinase 2 and cyclin D1 (48). However, in the present study, LEP was downregulated in DCIS tissues compared with normal tissues.

The remaining hub genes in the present study, including LIPE, PNPLA2 and DGAT2, were also expressed at low levels in DCIS tissues compared with normal breast tissues. However, these genes were not associated with the prognosis of patients with DCIS. It is worth noting that the GSE59248 dataset used in the present study contained the gene expression profiles of only three normal breast tissues. Therefore, future studies investigating the gene expression profiles from multiple datasets are warranted.

The present study investigated the differences between DCIS and normal breast tissues by integrating comprehensive

bioinformatics analyses. The top eight hub genes, namely LIPE, PNPLA2, ADIPOQ, PPARG, FABP4, DGAT2, LPL and LEP, were identified and considered to serve critical roles in the initiation of BC, while only five of the hub genes, ADIPOQ, PPARG, FABP4, LPL and LEP, were further found to be potential biomarkers for predicting the prognosis of patients with DCIS. However, further research is required to validate the results obtained in the present study.

## Acknowledgements

Not applicable.

## Funding

No funding was received.

## Availability of data and materials

The data that support the findings of this study are available from GEO database, DAVID, STRING and GEPIA database, as is mentioned in the Material and methods.

## Author's contributions

MW and ZHM analyzed the data and wrote the manuscript. ZHM supervised the study. Both authors read and approved the final manuscript.

## Ethics approval and consent to participate

Ethical approval was not necessary in this study because public datasets were analyzed.

## Patient consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## References

1. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW and Wender RC: Cancer screening in the United States, 2018: A review of current american cancer society guidelines and current issues in cancer screening. *CA Cancer J Clin* 68: 297-316, 2018.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68: 394-424, 2018.
3. Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA and Gomez SL: Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. *JAMA* 312: 902-914, 2014.
4. van der Veldt AA and Smit EF: Bevacizumab in neoadjuvant treatment for breast cancer. *N Engl J Med*. 366: 1637-1640, 2012.
5. Leal NF, Carrara HH, Vieira KF and Ferreira CH: Physiotherapy treatments for breast cancer-related lymphedema: A literature review. *Rev Lat Am Enfermagem* 17: 730-736, 2009.
6. Yeong J, Thihe AA, Tan PH and Iqbal J: Identifying progression predictors of breast ductal carcinoma in situ. *J Clin Pathol* 70: 102-108, 2016.

7. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, *et al*: Detection of ductal carcinoma in situ in women undergoing screening mammography. *J Natl Cancer Inst* 94: 1546-1554, 2002.
8. Sanders ME, Schuyler PA, Dupont WD and Page DL: The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. *Cancer* 103: 2481-2484, 2005.
9. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K and Aldaz CM: Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. *Breast Cancer Res* 6: R499-R513, 2004.
10. Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP and Carraro DM: Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. *Breast Cancer Res* 10: R87, 2008.
11. Schuetz CS, Michael B, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, *et al*: Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. *Cancer Res* 66: 5278-5286, 2006.
12. Choi Y, Lee HJ, Jang MH, Gwak JM, Lee KS, Kim EJ, Kim HJ, Lee HE and Park SY: Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. *Hum Pathol* 44: 2581-2589, 2013.
13. Shah S, Brock EJ, Jackson RM, Ji K, Boerner JL, Sloane BF and Mattingly RR: Downregulation of Rap1Gap: A switch from DCIS to invasive breast carcinoma via ERK/MAPK activation. *Neoplasia* 20: 951-963, 2018.
14. Sakr RA, Weigelt B, Chandarlapaty S, Andrade VP, Guerini-Rocco E, Giri D, Ng CK, Cowell CF, Rosen N, Reis-Filho JS and King TA: PI3K pathway activation in high-grade ductal carcinoma in situ-implications for progression to invasive breast carcinoma. *Clin Cancer Res* 20: 2326-2337, 2014.
15. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL and van de Vijver MJ: Classification of ductal carcinoma in situ by gene expression profiling. *Breast Cancer Res* 8: R61, 2006.
16. Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D and Thomas PD: PANTHER version 11: Expanded annotation data from gene ontology and reactome pathways, and data analysis tool enhancements. *Nucleic Acids Res* 45: D183-D189, 2017.
17. Huang da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 37: 1-13, 2009.
18. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, *et al*: The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res* 45: D362-D368, 2017.
19. Lesurf R, Aure MR, Mørk HH, Vitelli V, Oslo Breast Cancer Research Consortium (OSBREAC), Lundgren S, Børresen-Dale AL, Kristensen V, Wärnberg F, Hallett M and Sørli T: Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer. *Cell Rep* 16: 1166-1179, 2016.
20. Green GH and Diggle PJ: On the operational characteristics of the benjamini and hochberg false discovery rate procedure. *Stat Appl Genet Mol Biol* 6: Article27, 2007.
21. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Res* 13: 2498-2504, 2003.
22. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and Lin CY: CytoHubba: Identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* 8 (Suppl 4): S11, 2014.
23. Meghanathan N: Correlation coefficient analysis: Centrality vs. maximal clique size for complex real-world network graphs, 2016.
24. Györfy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Res Treat* 123: 725-731, 2010.
25. Tan PH: Pathology of ductal carcinoma in situ of the breast: A heterogeneous entity in need of greater understanding. *Ann The Acad Med Singap* 30: 671-677, 2001.
26. Gorringer KL and Fox SB: Ductal carcinoma in situ biology, biomarkers, and diagnosis. *Front Oncol* 7: 248, 2017.
27. Chung SJ, Nagaraju GP, Nagalingam A, Muniraj N, Kuppusamy P, Walker A, Woo J, Györfy B, Gabrielson E, Saxena NK and Sharma D: ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis. *Autophagy* 13: 1386-1403, 2017.
28. Divella R, Daniele A, Mazzocca A, Abbate I, Casamassima P, Caliandro C, Ruggeri E, Naglieri E, Sabbà C and De Luca R: ADIPOQ rs266729 G/C gene polymorphism and plasmatic adipocytokines connect metabolic syndrome to colorectal cancer. *J Cancer* 8: 1000-1008, 2017.
29. Canto P, Granados JB, Feria-Bernal G, Coral-Vázquez RM, García-García E, Tejeda ME, Tapia A, Rojano-Mejía D and Méndez JP: PPARGC1A and ADIPOQ polymorphisms are associated with aggressive prostate cancer in Mexican-Mestizo men with overweight or obesity. *Cancer Biomark* 19: 297-303, 2017.
30. Delort L, Jardé T, Dubois V, Vasson MP and Caldefie-Chézet F: New insights into anticarcinogenic properties of adiponectin: A potential therapeutic approach in breast cancer? *Vitam Horm* 90: 397-417, 2012.
31. He W: PPARGgamma2 polymorphism and human health. *PPAR Res* 2009: 849538, 2009.
32. Cruz SM and Balkwill FR: Inflammation and cancer: Advances and new agents. *Nat Rev Clin Oncol* 12: 584-596, 2015.
33. Robbins GT and Nie D: PPAR gamma, bioactive lipids, and cancer progression. *Front Biosci (Landmark Ed)* 17: 1816-1834, 2012.
34. Khandekar MJ, Cohen P and Spiegelman BM: Molecular mechanisms of cancer development in obesity. *Nat Rev Cancer* 11: 886-895, 2011.
35. Zhang S, Jiang J, Chen Z, Wang Y, Tang W, Chen Y and Liu L: Relationship of PPARG, PPARGC1A, and PPARGC1B polymorphisms with susceptibility to hepatocellular carcinoma in an eastern Chinese Han population. *Onco Targets Ther* 11: 4651-4660, 2018.
36. Xu W, Li Y, Wang X, Chen B, Liu S, Wang Y, Zhao W and Wu J: PPARGgamma polymorphisms and cancer risk: A meta-analysis involving 32,138 subjects. *Oncol Rep* 24: 579-585, 2010.
37. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC and Helzlsouer KJ: Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. *Cancer Detect Prev* 31: 95-101, 2007.
38. Wu MH, Chu CH, Chou YC, Chou WY, Yang T, Hsu GC, Yu CP, Yu JC and Sun CA: Joint effect of peroxisome proliferator-activated receptor gamma genetic polymorphisms and estrogen-related risk factors on breast cancer risk: Results from a case-control study in Taiwan. *Breast Cancer Res Treat* 127: 777-784, 2011.
39. Furuhashi M: Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. *J Atheroscler Thromb* 26: 216-232, 2019.
40. Li H, Xiao Y, Tang L, Zhong F, Huang G, Xu JM, Xu AM, Dai RP and Zhou ZG: Adipocyte fatty acid-binding protein promotes palmitate-induced mitochondrial dysfunction and apoptosis in macrophages. *Front Immunol* 9: 81, 2018.
41. Zhong CQ, Zhang XP, Ma N, Zhang EB, Li JJ, Jiang YB, Gao YZ, Yuan YM, Lan SQ, Xie D and Cheng SQ: FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. *Cancer Med* 7: 2629-2640, 2018.
42. Davies BS, Beigneux AP, Fong LG and Young SG: New wrinkles in lipoprotein lipase biology. *Curr Opin Lipidol* 23: 35-42, 2012.
43. Prieto D and Oppezzo P: Lipoprotein lipase expression in chronic lymphocytic leukemia: New insights into leukemic progression. *Molecules* 22: 2083, 2017.
44. Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzingen I, Mitteregger D, Le T, Gleiss A, Mannhalter C, *et al*: High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. *Leukemia* 19: 1216-1223, 2005.
45. Garofalo C and Surmacz E: Leptin and cancer. *J Cell Physiol* 207: 12-22, 2006.
46. Garofalo C, Sisci D and Surmacz E: Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. *Clin Cancer Res* 10: 6466-6475, 2004.
47. Hu X, Juneja SC, Maible NJ and Cleary MP: Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. *J Natl Cancer Inst* 94: 1704-1711, 2002.
48. Okumura M, Yamamoto M, Sakuma H, Kojima T, Maruyama T, Jamali M, Cooper DR and Yasuda K: Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: Reciprocal involvement of PKC-alpha and PPAR expression. *Biochim Biophys Acta* 1592: 107-116, 2002.

